Daiichi Sankyo Invests in Germany, Contrasting Other Pharma Exits

Japanese pharmaceutical company Daiichi Sankyo is increasing its investments in Germany, a move that stands in contrast to recent decisions by other major drug manufacturers like Eli Lilly and Boehringer Ingelheim to scale back their German operations.

Post Share

Sources

Showing 0 of 1 sources

No articles available in your preferred languages.

1 article available in other languages below.

fazGerman59d ago

Daiichi Sankyo investiert: Ein Pharmakonzern, der Deutschland treu bleibt

Zuletzt strichen die Arzneimittelhersteller Eli Lilly und Boehringer Ingelheim ihre Investitionsvorhaben in Deutschland spektakulär zusammen. Ein Wettbewerber aus Japan macht es anders.

Read full article →

PERSPECTA

PERSPECTA

Daiichi Sankyo Invests in Germany, Contrasting Other Pharma Exits

Sources

Daiichi Sankyo investiert: Ein Pharmakonzern, der Deutschland treu bleibt

Related Stories

Par Pacific to Sell Laramie Energy Assets for $485 Million

Executives at Precigen and RingCentral Sell Company Shares

Box Reports Strong Q2 2026 Revenue, Lifts Full-Year Outlook

ECB and BOJ Expected to Raise Interest Rates in September

PERSPECTA